Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects

Anthony G Mansour, Ying Huang, Aseel Alsouqi, Adam S Kittai, John C. Byrd, Michael R. Grever, Cecelia Miller, Gerard Lozanski, Mollie Moran, Margaret S. Lucas, Swetha Suresh, Cara Grantier, Corinne Hoffman, Mark Reid, Kerry A. Rogers, Seema A Bhat, Jennifer A. Woyach

Blood (2024) 144 (Supplement 1): 4629.

https://doi.org/10.1182/blood-2024-199676

Published: 2024

Journal Articles

Extended Follow up of a Phase 2 Study of Early Intervention with Lenalidomide in Patients with High-Risk Chronic Lymphocytic Leukemia

Kerry A Rogers, Qiuhong Zhao, Seema A Bhat, John C. Byrd, Cara Grantier, Michael R. Grever, Corinne Hoffman, Adam S Kittai, Gerard Lozanski, Margaret S. Lucas, Lindsey Rike, Shanmugapriya Thangavadivel, William E. Carson III, Jennifer A. Woyach

Blood (2023) 142 (Supplement 1): 3272.

https://doi.org/10.1182/blood-2023-180308

Published: 2023

Journal Articles

Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study

Isaac Esplin, Ying Huang, Seema A. Bhat, Cara Grantier, Michael R. Grever, Corinne Hoffman, Adam S Kittai, Margaret S. Lucas, Mollie E. Moran, Mark Reid, Swetha Suresh, Jennifer A. Woyach, Kerry A. Rogers

Blood (2022) 140 (Supplement 1): 4166–4168.

https://doi.org/10.1182/blood-2022-167314

Published: 2022

Journal Articles

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Blood (2016) 128 (22): 55.

https://doi.org/10.1182/blood.V128.22.55.55

Published: 2016

Journal Articles

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101.

Thomas S Lin, MD, PhD, Kathleen A Donohue, John C. Byrd, MD, Margaret S Lucas, Eva Hoke, Elizabeth M Bengtson, MD, James N Atkins, MD, Brian K Link, MD, Kanti R Rai, MD, Richard A Larson, MD

Blood (2009) 114 (22): 210.

https://doi.org/10.1182/blood.V114.22.210.210

Published: 2009

Journal Articles

A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma

Kristie A. Blum, MD, Robert A. Baiocchi, Lapo Alinari, Thomas S. Lin, Pierluigi Porcu, Jeffrey Jones, Joseph Flynn, William Hicks, Margaret S. Lucas, Lai Wei, Jeffrey S. Johnston, John C. Byrd

Blood (2008) 112 (11): 3053.

https://doi.org/10.1182/blood.V112.11.3053.3053

Published: 2008

Journal Articles

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101.

Thomas S. Lin, MD, PhD, Kathleen A. Donohue, MA, Margaret S. Lucas, BS, PA, John C. Byrd, MD, Elizabeth M. Bengtson, MD, Bercedis L. Peterson, PhD, Richard A. Larson, MD

Blood (2007) 110 (11): 755.

https://doi.org/10.1182/blood.V110.11.755.755

Published: 2007

Journal Articles

The Addition of CT Scans to NCI-96 Chronic Lymphocytic Leukemia (CLL) Response Criteria Fails To Improve the Predictive Power of Complete Response (CR) and Partial Response (PR) as Assessed by Improvement in Progression-Free (PFS) and Overall Survival (OS) .

Kristie A. Blum, MD, Donn Young, PhD, Sarah Broering, Margaret S. Lucas, Thomas S. Lin, MD, PhD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2006) 108 (11): 2833.

https://doi.org/10.1182/blood.V108.11.2833.2833

Published: 2006

Journal Articles

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.

Thomas S. Lin, MD, PhD, Margaret S. Lucas, PA-C, Nyla A. Heerema, PhD, Jennifer J. Matkovich, BS, Mollie E. Moran, CNP, Carolyn Cheney, BS, David M. Lucas, PhD, Donn C. Young, PhD, Michael A. Caligiuri, MD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2006) 108 (11): 2841.

https://doi.org/10.1182/blood.V108.11.2841.2841

Published: 2006

Journal Articles

Excessive Neurotoxicity in a Phase II Trial of Combined Bortezomib and Rituximab in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma.

Kristie A. Blum, MD, Margaret S. Lucas, Jeffrey S. Johnston, PhD, James Dalton, PhD, Donn Young, PhD, Robert A. Baiocchi, MD, PhD, Thomas S. Lin, MD, PhD, Pierluigi Porcu, MD, John C. Byrd, MD

Blood (2006) 108 (11): 2768.

https://doi.org/10.1182/blood.V108.11.2768.2768

Published: 2006

Journal Articles

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia

Thomas S. Lin, Ian W. Flinn, Rama Modali, Teresa A. Lehman, Jennifer Webb, Sharon Waymer, Mollie E. Moran, Margaret S. Lucas, Sherif S. Farag, John C. Byrd

Blood (2005) 105 (1): 289–291.

https://doi.org/10.1182/blood-2004-02-0651

Published: 2005

Journal Articles

Effects of the Redox Mediator Motexafin Gadolinium in a Pilot Phase I Trial in Refractory Chronic Lymphocytic Leukemia (CLL).

Thomas S. Lin, MD, PhD, Sabyasachi Biswas, PhD, Louie Naumovski, MD, PhD, Phillip Lecane, PhD, Margaret S. Lucas, PA-C, Mollie E. Moran, CRNP, Andrew P. Mone, MD, PhD, David M. Lucas, PhD, See-Chun Phan, MD, Richard A. Miller, MD, John C. Byrd, MD

Blood (2004) 104 (11): 3486.

https://doi.org/10.1182/blood.V104.11.3486.3486

Published: 2004

Journal Articles

Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL).

John C. Byrd, MD, Thomas S. Lin, MD, Phd, James T. Dalton, PhD, Di Wu, PhD, Beth Fischer, MSN, Mollie E. Moran, CRNP, Kristie A. Blum, MD, Roshini S. Shank, BA, David M. Lucas, PhD, Margaret S. Lucas, PA-C, Jose-Ramon Suarez, MD, Michael R. Grever, MD

Blood (2004) 104 (11): 341.

https://doi.org/10.1182/blood.V104.11.341.341

Published: 2004

Journal Articles

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities.

Thomas S. Lin, MD, PhD, Nyla A. Heerema, PhD, Jennifer Swenor, Margaret S. Lucas, PA-C, Mollie E. Moran, CRNP, Carolyn M. Cheney, MS, David M. Lucas, PhD, Donn Young, PhD, Michael A. Caligiuri, MD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2004) 104 (11): 3469.

https://doi.org/10.1182/blood.V104.11.3469.3469

Published: 2004

Journal Articles

Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.

Thomas S. Lin, MD, PhD, Beth Fischer, MSN, Mollie E. Moran, CRNP, David M. Lucas, PhD, Roshini S. Shank, BA, Eric H. Kraut, MD, Sheriff S. Farag, MD, PhD, Margaret S. Lucas, PA-C, Alexander D. Colevas, MD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2004) 104 (11): 2492.

https://doi.org/10.1182/blood.V104.11.2492.2492

Published: 2004

NARROW

Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects

Extended Follow up of a Phase 2 Study of Early Intervention with Lenalidomide in Patients with High-Risk Chronic Lymphocytic Leukemia

Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101.

The Addition of CT Scans to NCI-96 Chronic Lymphocytic Leukemia (CLL) Response Criteria Fails To Improve the Predictive Power of Complete Response (CR) and Partial Response (PR) as Assessed by Improvement in Progression-Free (PFS) and Overall Survival (OS) .

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.

Excessive Neurotoxicity in a Phase II Trial of Combined Bortezomib and Rituximab in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma.

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia

Effects of the Redox Mediator Motexafin Gadolinium in a Pilot Phase I Trial in Refractory Chronic Lymphocytic Leukemia (CLL).

Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL).

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities.

Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only